Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7705509 | 0.98 | HSD11B1 (0.44) | HSD11B1CHRNA7MAPK1LMNACYP2C9 | |
| SCHEMBL12022394 | 0.75 | MAPK1 (0.43) | CHRNA7MAPK1LMNACYP2C9SLC6A3 | |
| SCHEMBL15028241 | 0.74 | SLC6A4 (0.37) | MAPK1CHRM2CHRM1CHRM3SLC6A3 | |
| SCHEMBL1114394 | 0.73 | MAPK1 (0.41) | CHRNA7MAPK1LMNACYP2C9CHRM3 | |
| Hydrochloric Acid SCHEMBL7809740 | 0.71 | CHRNA7 (0.40) | CHRNA7MAPK1LMNACYP2C9CHRM3 | |
| SCHEMBL15177769 | 0.70 | HSD11B1 (0.33) | HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL13547441 | 0.69 | CHRM2 (0.45) | HSD11B1CHRNA7CHRM2SLC6A2CHRM4 | |
| SCHEMBL9874815 | 0.69 | MAPK1 (0.43) | CHRNA7MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL7893573 | 0.68 | NOS3 (0.31) | HSD11B1 | |
| SCHEMBL18323812 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0445731-B1 | Azabicyclo and azacyclo oxime and amine cholinergic agents and pharmaceutically acceptable salts thereof | WARNER LAMBERT CO (US) | 1996-01-10 | — | — | EP | claimed |
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| EP-0772613-B1 | PROCESS FOR THE PRODUCTION OF AMINOAZOBICYCLOALKANES FROM OXIMES | HOFFMANN LA ROCHE (CH) | 2001-11-21 | — | — | EP | disclosed |
| EP-0772613-A2 | PROCESS FOR THE PRODUCTION OF AMINOAZOBICYCLOALKANES FROM OXIMES | SMITHKLINE BEECHAM PLC (GB) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003401-A2 | PROCESS FOR THE PRODUCTION OF AMINOAZOBICYCLOALKANES FROM OXIMES | SMITHKLINE BEECHAM PLC (GB) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | HSD11B1 4665/4885CHRNA7 4376/4885MAPK1 500/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | HSD11B1 4665/4885CHRNA7 4376/4885MAPK1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.